Full Press Release Details
News
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases
« Go Back
About Us
Pipeline
News
Investors
Contact Us
CUE Positive Sentiment
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases
Key Takeaway: Boehringer Ingelheim has partnered with Cue Biopharma to develop a next-generation treatment targeting autoimmune and inflammatory diseases. This collaboration aims to combine the expertise of both companies to enhance therapeutic options in this area. The partnership is expected to drive innovation in treatment methodologies.
Price reaction · baseline $39.6 (2025-02-21 close) · hit pre-market · clean, no other CUE news in the window
day 0 close · peak
-3.8%
Market Sentiment Analysis
POSITIVE FACTORS
- Collaboration aims to advance treatment options for autoimmune diseases.
- Partnership leverages strengths of both Boehringer Ingelheim and Cue Biopharma.
- Focus on next-generation therapies could lead to innovative solutions.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+253%
120-day peak, hindsight
Typical move
10.2%
average across 2 past catalysts
Cash runway
~2 mo
High dilution risk
Lead asset
CUE-101
Phase 2 · Head and Neck Squamous Cell Carcinoma
Frequently Asked Questions
What is the focus of the Boehringer and Cue partnership?
The partnership focuses on developing next-generation treatments for autoimmune and inflammatory diseases.
Who are the partners in this collaboration?
The collaboration is between Boehringer Ingelheim and Cue Biopharma.
What is the goal of this partnership?
The goal is to combine expertise to enhance therapeutic options in autoimmune diseases.